Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours.

ABSTRACT:

Aim

Patients with cancer are at an increased risk for severe coronavirus disease of 2019. We previously reported initial findings from a single centre prospective study evaluating antibody response after BNT162b2 vaccine, showing that adequate antibody response was achieved after two doses, but not after one, in patients with cancer vaccinated during anticancer therapy. Herein, we report a follow-up study, evaluating antibody response six months after the second vaccine dose.

Methods

The study included patients with solid tumours undergoing anticancer treatment, and immunocompetent health-care workers serving as controls. Serum titres of the receptor-binding domain (RBD) IgG and neutralising antibodies (Nabs) were measured approximately six months after the second vaccine do

SUBMITTER: Margalit O 

PROVIDER: S-EPMC9013177 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature